Skip to content
Screener

Stoke Therapeutics, Inc. STOK Total Liabilities & Equity

Total Liabilities & Equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$2.99B+0.3%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$11.86B+2.8%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$1.3B+92.2%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$1.39B+207%
CalAmp logo
CalAmpCAMP
$105.46M+68.0%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$1.27B+20.5%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Cash & equivalents$155.7M-43.4%
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0.0×
Current ratio+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemMarch 31, 2026December 31, 2025
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively65
Additional paid-in capital942,704849,624
Accumulated other comprehensive (loss) income(115)543
Accumulated deficit(547,718)(497,715)
Total stockholders’ equity$394,877$352,457
Total liabilities and stockholders’ equity$443,277$418,434

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s total liabilities & equity?
Stoke Therapeutics, Inc. (STOK) reported total liabilities & equity of $443.28M in Q1 2026.
How has Stoke Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Stoke Therapeutics, Inc.'s total liabilities & equity increased by 8.9% year-over-year, from $406.89M to $443.28M.
What is the long-term trend for Stoke Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s total liabilities & equity has grown at a 7.0% compound annual growth rate (CAGR), from $297.93M to $418.43M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Stoke Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude